Latest Johnson & Johnson Pharmaceutical Research & Development L.L.C. Stories
SAN DIEGO, Aug. 4, 2011 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) announced today the publication of research that uncovered a previously unknown role for a class of molecules that could lead to future advances in immunologic medicine.
RARITAN, N.J., July 1, 2011 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. announced today that the U.S.
CHICAGO, June 3, 2011 /PRNewswire/ -- Data related to ZYTIGA(TM) (abiraterone acetate) will be presented at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
TITUSVILLE, N.J., April 11, 2011 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) on April 6 approved INVEGAÂ® (paliperidone) extended-release tablets for the treatment of schizophrenia in adolescents 12 to 17 years of age.
BEERSE, Belgium, Dec. 1, 2010 /PRNewswire/ -- Janssen Pharmaceutica N.V., (Janssen) today announced a research agreement to collaborate with GE Healthcare to develop non-invasive or minimally invasive diagnostic biosignatures to detect Alzheimer's disease prior to the onset of clinical symptoms.
CHICAGO, Nov. 15, 2010 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
TITUSVILLE, N.J., Nov. 2, 2010 /PRNewswire/ -- Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI) today announced it has entered into a supply and distribution agreement with Watson Laboratories, Inc.